Insider Buying: Neonc Technologies (NASDAQ:NTHI) President Acquires $56,100.00 in Stock
by Teresa Graham · The Cerbat GemNeonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) President Amir Heshmatpour purchased 10,000 shares of the business’s stock in a transaction on Wednesday, April 8th. The stock was purchased at an average cost of $5.61 per share, with a total value of $56,100.00. Following the acquisition, the president owned 3,027,000 shares in the company, valued at approximately $16,981,470. This represents a 0.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Neonc Technologies Price Performance
Shares of NASDAQ:NTHI opened at $5.44 on Friday. Neonc Technologies Holdings, Inc. has a 1-year low of $3.20 and a 1-year high of $12.99. The business’s 50 day moving average is $8.56 and its 200-day moving average is $9.05.
Hedge Funds Weigh In On Neonc Technologies
Hedge funds have recently modified their holdings of the stock. 683 Capital Management LLC acquired a new stake in Neonc Technologies in the 4th quarter valued at $442,000. OMERS ADMINISTRATION Corp acquired a new position in Neonc Technologies during the fourth quarter worth $126,000. Barclays PLC raised its stake in Neonc Technologies by 5,314.8% during the fourth quarter. Barclays PLC now owns 9,151 shares of the company’s stock worth $76,000 after acquiring an additional 8,982 shares in the last quarter. State Street Corp lifted its holdings in shares of Neonc Technologies by 9.9% during the fourth quarter. State Street Corp now owns 43,170 shares of the company’s stock valued at $357,000 after acquiring an additional 3,900 shares during the period. Finally, Goldman Sachs Group Inc. bought a new position in shares of Neonc Technologies during the fourth quarter valued at $124,000.
Wall Street Analyst Weigh In
Several brokerages have issued reports on NTHI. Zacks Research raised shares of Neonc Technologies to a “hold” rating in a report on Wednesday, January 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neonc Technologies in a report on Friday, March 27th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.
View Our Latest Analysis on NTHI
Neonc Technologies Company Profile
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.